Visijet Inc. Files For FDA Approval Of Epi-Tome; Product Currently Being Sold In Europe And Korea; Addresses $4 Billion Refractive Surgery Market
10/19/2005 5:11:42 PM
VisiJet Inc. (OTCBB:VJET), developers of innovative technologies for the ophthalmic surgical market, announced today that a 510K filing has been made with the FDA for approval of the Epi-Tome(TM), a next-generation, ophthalmic surgical tool designed for cutting and separating corneal tissue. The company recently acquired worldwide distribution rights for the product from Gebauer Medizintechnik GmbH of Neuhausen, Germany.
comments powered by